| Identification | Back Directory | [Name]
SERGLIFLOZIN | [CAS]
408504-26-7 | [Synonyms]
KGT1251
KGT-1251
GW869682
GW-869682
GW869682X
GW-869682X
SERGLIFLOZIN
Sergliflozin etabonate
QLXKHBNJTPICNF-QMCAAQAGSA-N
2-(4-Methoxybenzyl)phenyl6-O-(ethoxycarbonyl)-beta-D-glucopyranoside
β-D-Glucopyranoside,2-[(4-methoxyphenyl)methyl]phenyl,6-(ethyl carbonate)
β-D-Glucopyranoside,2-[(4-Methoxyphenyl)Methyl]phenyl,6-(ethyl carbonate)
2-[(4-Methoxyphenyl)methyl]phenyl-beta-D-glucopyranoside-6-(ethyl carbonate)
ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate | [Molecular Formula]
C23H28O9 | [MDL Number]
MFCD13182360 | [MOL File]
408504-26-7.mol | [Molecular Weight]
448.46 |
| Hazard Information | Back Directory | [Uses]
Treatment of type 2 diabetes. | [Definition]
ChEBI: Sergliflozin etabonate is a glycoside. | [in vivo]
Sergliflozin etabonate (1, 3, 10, 30 mg/kg; oral; once) significantly reduces non-fasting blood glucose levels in KK-Ay mice in a dose-dependent manner[1].
Sergliflozin etabonate (1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate; fed; daily for 9 weeks) reduces non-fasting blood glucose level and decreases triglyceride content in the liver in a dose-dependent manner in KK-Ay mice[1]. | Animal Model: | 14 weeks, Female KK-Ay mice[1] | | Dosage: | 1, 3, 10, 30 mg/kg | | Administration: | Oral; once | | Result: | Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively. |
| Animal Model: | 4 weeks, Female KK-Ay mice[1] | | Dosage: | 1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate | | Administration: | Fed, daily for 9 weeks | | Result: | Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice. |
| [IC 50]
SGLT2 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|